Stay updated with breaking news from Aridis Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aridis Pharmaceuticals, Inc. (ARDS) announced Monday preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections.
Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode News provided by Share this article Share this article LOS GATOS, Calif., March 8, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. Kermode works on vaccines and mAbs for zoonotic viruses, which are animal viruses that have the ability to infect humans. Under the terms of the agreement, the activities of each party and the products discovered using Ari...